Astellas Pharma Inc. today announced that it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of Astellas as of CET May 17, 2017.
Under the share purchase agreement executed between Astellas and Ogeda shareholders, Astellas paid EUR 500 million to acquire 100% of the equity in Ogeda. In addition, Ogeda shareholders will become eligible to receive up to EUR 300 million in further contingent payments based on progress in the development of fezolinetant, Ogeda’s most advanced clinical program for the treatment of menopausal-related vasomotor symptoms.
This transaction expands Astellas’ late stage pipeline and is expected to contribute to its mid-to-long term growth.
Astellas reflected the impact from this closing of transaction in its financial forecasts of the current fiscal year ending March 31, 2018
Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.
Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.
Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.